Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth
- PMID: 16941672
- DOI: 10.1002/pros.20476
Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth
Abstract
Background: Angiogenic and angiostatic CXC chemokines mediate their effects via the receptors, CXCR2 and CXCR3, respectively. The current study sought to determine whether the presence of these receptors alters prostate tumor growth.
Methods: Endothelial cell chemotaxis of prostate cell-derived products was determined in vitro. Transgenic adenocarcinoma of the mouse prostate (TRAMP) mice was bred with CXCR2- or CXCR3-knockout mice to determine the effects of these genes on prostate tumor growth.
Results: Normal prostate epithelial cells release CXCR3 ligands that limit endothelial cell chemotaxis. Prostate cancer cells release CXCR2 ligands that stimulated endothelial cell chemotaxis. Tumors in TRAMP/CXCR2(-/-) mice were significantly smaller than those in TRAMP/CXCR2(+/+) mice and had reduced angiogenesis. In contrast, tumors in TRAMP/CXCR3(-/-) mice were palpable much earlier than TRAMP/CXCR3(+/+) mice and had greatly increased angiogenesis.
Conclusions: The data suggest that signaling through CXCR2 and CXCR3 represents important counter-regulatory mechanisms that control the growth of prostate tumors.
Similar articles
-
Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade.Cancer Res. 2004 Sep 1;64(17):6137-43. doi: 10.1158/0008-5472.CAN-04-1287. Cancer Res. 2004. PMID: 15342397
-
Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model.Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1130-7. doi: 10.1161/01.ATV.0000129537.72553.73. Epub 2004 Apr 22. Arterioscler Thromb Vasc Biol. 2004. PMID: 15105284
-
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras.Cancer Res. 2006 Apr 15;66(8):4198-207. doi: 10.1158/0008-5472.CAN-05-3842. Cancer Res. 2006. PMID: 16618742
-
Chemokine receptor CXCR3: an unexpected enigma.Curr Top Dev Biol. 2005;68:149-81. doi: 10.1016/S0070-2153(05)68006-4. Curr Top Dev Biol. 2005. PMID: 16124999 Review.
-
CXC chemokines in vascular remodeling related to pulmonary fibrosis.Am J Respir Cell Mol Biol. 2003 Sep;29(3 Suppl):S67-9. Am J Respir Cell Mol Biol. 2003. PMID: 14503558 Review. No abstract available.
Cited by
-
CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-κB activation via EGFR-transactivated Akt signaling.PLoS One. 2013 Dec 20;8(12):e83789. doi: 10.1371/journal.pone.0083789. eCollection 2013. PLoS One. 2013. PMID: 24376747 Free PMC article.
-
Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.Endocr Relat Cancer. 2012 May 24;19(3):321-31. doi: 10.1530/ERC-11-0368. Print 2012 Jun. Endocr Relat Cancer. 2012. PMID: 22389383 Free PMC article.
-
The Ron receptor promotes prostate tumor growth in the TRAMP mouse model.Oncogene. 2011 Dec 15;30(50):4990-8. doi: 10.1038/onc.2011.205. Epub 2011 May 30. Oncogene. 2011. PMID: 21625214 Free PMC article.
-
CXCR3 enhances a T-cell-dependent epidermal proliferative response and promotes skin tumorigenesis.Cancer Res. 2011 Sep 1;71(17):5707-16. doi: 10.1158/0008-5472.CAN-11-0907. Epub 2011 Jul 6. Cancer Res. 2011. PMID: 21734014 Free PMC article.
-
Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.Onco Targets Ther. 2018 May 28;11:3167-3178. doi: 10.2147/OTT.S159777. eCollection 2018. Onco Targets Ther. 2018. PMID: 29881290 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
